Investment Thesis
REST EZ Inc. exhibits complete operational collapse with zero revenue, zero operating cash flow, and zero profitability across all metrics. The company functions as a cash shell with minimal assets and no evidence of active pharmaceutical operations or business recovery prospects.
Strengths
- Zero financial leverage (0.0x debt/equity)
- Modest cash reserves ($300k) provides temporary runway
- Recent financial data available for analysis
Risks
- Total revenue loss (-100% YoY) with zero current sales
- Zero operating cash flow indicates inability to sustain operations
- Minimal total assets ($300k) insufficient to fund pharmaceutical development
- No insider trading activity in 90 days signals loss of management confidence
- Rapid cash depletion inevitable without business operations
- Pharmaceutical sector requires substantial capital with no evidence of investment
Key Metrics to Watch
- Revenue reinstatement or operational restart
- Operating cash flow generation timeline
- Cash burn rate and months of runway remaining
Financial Metrics
Revenue
0.0
Net Income
0.0
EPS (Diluted)
$0.00
Free Cash Flow
0.0
Total Assets
300.0
Cash
300.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
0.0%
ROA
0.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T04:09:20.308438 |
Data as of: 2025-12-31 |
Powered by Claude AI